soidal flow and perfusion (4, 12, 21) . Furthermore, eNOS-derived NO production is altered in vascular diseases in the liver (13, 19) . For example, in liver cirrhosis and portal hypertension, a syndrome characterized by increased intrahepatic vasoconstrictive responses and impaired vasodilation, a deficit in hepatic NO production, has been demonstrated (8, 16, 22, 23) . Prior studies have also supported the concept that deficient function of eNOS in the cirrhotic liver may be mediated by inhibitory factors within the cirrhosis milieu, perhaps through the NOS inhibitory protein caveolin (22, 23, 31) .
The mechanism of eNOS-derived NO generation requires diverse posttranslational events, and recent studies indicate that the phosphorylation of the serine residue at amino acid (AA) 1179 on eNOS is one of the important steps in the process of eNOS activation (5, 6) . In this regard, mutation of AA1179 in eNOS from a serine to aspartate modifies the calcium activation characteristics of the enzyme, resulting in a constitutively active form of eNOS (S1179DeNOS) that produces excess levels of NO compared with the wild-type eNOS (11, 18) . Alternatively, mutation of serine 1179 to alanine in eNOS (S1179AeNOS) mimics a nonphosphorylated form of eNOS (11) .
In this study, we analyzed the function of S1179DeNOS in liver cells in vitro and in vivo through the use of an adenoviral vector encoding S1179DeNOS (AdS1179DeNOS). We demonstrated that overexpression of S1179DeNOS in both isolated liver cell populations and in sham liver stimulates NO generation and vasodilatory responses, respectively, but does not improve vasodilatory responses in cirrhotic rats, despite similar hepatic transgene expression within the two groups. Immunoelectron microscopy studies detect the eNOS inhibitory protein caveolin in sinusoidal lining cells in the bile duct-ligated (BDL) liver, including hepatic stellate cells, a prominent target of adenoviral vectors in vivo. In vitro studies in the LX2 hepatic stellate cell line indicate that caveolin binds recombinant S1179DeNOS and that overexpression of caveolin further potentiates binding of the two proteins from cell lysates in conjunction with reducing the activity of recombinant S1179DeNOS. These studies thereby suggest that the lack of vasodilatory effect of recombinant S1179DeNOS in BDL liver may be mediated through caveolin upregulation and ensuing S1179DeNOS inhibition in sinusoidal lining cells, including hepatic stellate cells.
MATERIALS AND METHODS

Animals and reagents.
Animal experiments (male Fisher rats, Harlan Sprague Dawley Laboratories, Indianapolis, IN) and serum/tissue harvesting were performed in accordance with the animal care guidelines of the institution. BDL and sham surgeries were performed as previously described (22) . The previously characterized replication incompetent serotype 5 adenoviral vectors, driven by the cytomegalovirus immediate early promoter, were used in these studies: AdS1179DeNOS encoded cDNA sequences for green fluorescent protein (GFP) and S1179DeNOS, AdS1179AeNOS encoded sequences for GFP and S1179AeNOS, AdGFP encoded sequence for GFP alone, and AdCav encoded an myc-tagged caveolin-1 construct (18, 25) . Amplification, purification, and titering of viruses were performed as previously described (20) . Methoxamine (MTX) and Ca 2ϩ ionophore A23187 (both from Sigma, St. Louis, MO) were dissolved in distilled water and DMSO, respectively, and the equivalent volume of vehicle was used in control experiments. All tissue culture reagents including DMEM, MEM, FBS, penicillin, and streptomycin were obtained from GIBCO.
Adenoviral gene delivery in vitro and in vivo.
For in vitro transduction, hepatocytes and nonparenchymal cells (NPC) were isolated and cultured as described previously (20, 22) using a collagenase perfusion technique. With the use of this approach, exclusion of NPC from the hepatocyte fraction and hepatocytes from the NPC fraction was consistently Ͼ95%. For in vitro NPC transduction, the freshly isolated NPC pellet was suspended in DMEM containing 10% FBS, and cells were plated at a density of 10 6 /ml culture media on 60-mm collagen-coated plastic tissue culture dishes or glass coverslips and placed in a 37°C, 5% CO 2 incubator. Four hours after plating, cells were washed with PBS and transduced with PBS/0.1% albumin containing 50 multiplicity of infection (MOI) of AdS1179D or AdGFP for 1 h. The vector solution was then aspirated, and after being washed with PBS, complete culture medium was replenished. Twenty-four hours after transduction, culture media were collected to analyze basal NO accumulation, and cells were lysed and prepared for protein analysis, fixed, and prepared for epifluorescence microscopy to detect GFP or alternatively prepared for measurement of A23187-stimulated NO release. Each of these techniques is described below. Transduction and media collection from hepatocytes was performed in an analogous manner using the vectors described above as well as an adenoviral vector encoding an eNOS construct, which mimics a nonphosphorylated form of eNOS (mutation of serine 1179 to alanine), AdS1179AeNOS (11) . Cotransduction experiments were performed in LX2 cells, a well-characterized hepatic stellate cell line (27, 30) , which were transduced with both AdS1179DeNOS and AdCav or with one of the above in conjunction with an empty vector using procedures and viral titers identical to that described above. For in vivo studies, adenoviruses were diluted in saline and administered intravenously via the tail vein ϳ4 wk after surgery at a titer of 10 10 plaque-forming units (pfu)/rat administered in a volume of 50-100 l followed by 100 l saline flush. All rats weighed ϳ250 g. This titer was selected based on previous studies (20) performed to optimize in vivo transduction, which indicated that lower titers of adenovirus resulted in suboptimal transduction, whereas higher titers were associated with histological evidence of inflammatory cell infiltration in liver of some animals. One week after injection of the virus, animals were killed for biochemical and pharmacological studies as described below.
Fluorimetry from liver lysates. Liver tissue GFP levels were measured from transduced animals to confirm adenoviral-mediated overexpression of transgene. Liver tissues were homogenized in a lysis buffer [50 mM Tris ⅐ HCl, 0.1 mM EGTA, 0.1 mM EDTA, 2 M leupeptin, 1 mM PMSF, 1% (vol/vol) Nonidet P-40 (NP-40), 0.1% SDS, 0.1% deoxycholate, pH 7.5] (22), and protein quantification of samples was performed using the Lowry assay. GFP was quantified by measuring fluorescence intensity from aliquots of liver lysates in each of the experimental groups using a fluorimeter (VersaFluor Flurometer, BioRad) (24). Samples were analyzed in microcuvettes at excitation of 490 nm and emission of 520 nm with duplicate readings from duplicate wells and normalized for cellular protein content. The negative control sample included normal rat liver lysate, whereas the positive control sample included liver lysate derived from a transgenic mouse that constitutively expresses GFP in liver (17) .
Measurement of NO production. Hepatocytes and NPC were transduced with adenoviral vectors as described above. Basal NO production was assessed from NPC by measuring NO accumulation in the supernatant during the 24 h immediately following adenoviral transduction by collecting the media, and assessing levels of the stable NO byproduct nitrite by the Greiss reaction. Subsequently, agonist-stimulated NO production was assessed by incubating transduced cells with calcium ionophore A23187 (10 M). After 1 h, supernatant was collected and analyzed for nitrite using NO-specific chemiluminescence (Seivers NOA, Boulder, Colorado). NO-specific chemiluminescence and Greiss reaction were performed as previously described (1, 20, 21) . For both methods, a standard curve generated using known nitrite standards was performed in parallel with samples, which were analyzed in duplicate and then normalized for cellular protein.
Liver perfusion studies. Analysis of hepatic vascular responses was performed 1 wk after in vivo adenoviral transduction experiments using the isolated perfused rat liver preparation (20, 23) . After laparotomy, ligatures were placed around the portal vein and infrahepatic inferior vena cava (IVC). The portal vein was cannulated and perfused through a 16-g angiocath, and the IVC distal to the ligature was ligated allowing the perfusate to escape. A loose ligature was then placed around the suprahepatic IVC before tying the prehepatic IVC. The redirected perfusate was allowed to escape through a 16-g catheter passed through the right atrium into the suprahepatic IVC. The secured liver preparation was then transferred to an enclosed 37°C perfusion apparatus. The liver was perfused ex vivo through the portal vein with Krebs solution [in mM: 118.3 NaCl, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, 25 NaHCO3, and 11.1 glucose, with 2 U/ml heparin (pH 7.4)] oxygenated with 95% O2-5% CO2 at 37°C, which was recirculated at 20 ml/min with continuous perfusion pressure monitoring (Sys-200/1 Micro-Med). Global viability of the preparation was assessed by gross appearance of the tissue, stable pH of the perfusate, and stable perfusion pressure for 10 m before administration of compounds. Perfusion pressure changes in response to a vasoconstrictor were assessed by cumulative addition of MTX to the perfusate (10 Ϫ6 to 10 Ϫ4 M) (20) . Perfusion pressure changes in response to flow were performed as previously described (23) by increasing the flow rate from 20 to 40 ml/min in increments of 10 ml/min.
Fluorescence microscopy. Fluorescence microscopy for detection of GFP protein was performed as previously described (1) . In brief, NPC transduced with AdGFP were fixed in 2% paraformaldehyde, mounted in Anti-fade (Molecular Probes, Eugene, OR), and GFP was detected using a conventional fluorescence microscope (5100TV; Zeiss, Germany).
Transmission electron microscopy and immunogold analysis. For morphological examination of sham and BDL liver, tissues were fixed in Trump's fixative (1% glutaraldehyde and 4% formaldehyde in 0.1 M phosphate buffer, pH 7.2). Tissue was then rinsed for 30 min in three changes of 0.1 M phosphate buffer, pH 7.2, followed by a 1-h postfix in phosphate-buffered 1% OsO 4. After being rinsed in three changes of distilled water for 30 min, the tissue was en bloc stained with 2% uranyl acetate for 30 min at 60°C. After being en bloc stained, the tissue was rinsed in three changes of distilled water, dehydrated in progressive concentrations of ethanol and 100% propylene oxide, and embedded in Spurr's resin. Thin (90 nm) sections were cut on a Reichert Ultracut E ultramicrotome, placed on 200 mesh copper grids, and stained with lead citrate. Samples for immunogold analysis were prepared as previously described (9) with minor modifications. In brief, the specimens were fixed in 4% formaldehyde and 0.2% gluaraldehyde in phosphate buffer and rinsed in phosphate buffer. Dehydration was done in a series of ethyl alcohols ranging from 60 to 80%, while progressively lowering the temperature to Ϫ20°C. After two changes in 100% LR White resin, the specimen was embedded and the resin was polymerized at 55°C. Thin sections were mounted on nickel grids and dried overnight. Nonspecific antigen sites were blocked first in 1% glycine then in PBS and 0.05% Tween 20 (PBST) with 2% acetylated bovine serum albumin. Caveolin polyclonal antibody (PAb) (Transduction Laboratories, Lexington KY) was diluted 1:100 in PBST, and sections were incubated in primary antibody for 2 h at room temperature. Lung tissue, which is highly enriched in caveolin, was used as a positive control, whereas negative control samples were examined in the absence of PAb. Grids were rinsed in PBST and incubated for 60 min in secondary antibody (goat anti-rabbit) conjugated to 5 nm colloidal gold. The grids were rinsed sequentially in PBST and water and then silverenhanced for 20 min. The sections were then stained with uranyl and lead. Micrographs were taken on a JEOL 1200 EXII operating at 60 KV at magnification ranging from ϫ5,000 to ϫ50,000.
Immunoprecipitation and Western blotting. Twenty-four hours after adenoviral transduction, LX2 cells were homogenized in a lysis buffer [in mM: 50 Tris ⅐ HCl, 0.1 EGTA, 0.1 EDTA, 100 leupeptin, and 1 PMSF, with 1% (vol/vol) NP-40 and 0.1% deoxycholic acid (pH 7.5)] (23). Protein quantification of samples was performed using the Lowry assay. Immunoprecipitation was performed by incubating equal aliquots of detergent-soluble protein lysate from whole liver with excess eNOS MAb or caveolin PAb (Transduction Laboratories) overnight, after preclearing of samples with Pansorbin (23) . Immunocomplexes were bound by incubating protein samples with Protein A beads for 1 h at 4°C. Complexes were washed three times in the lysis buffer described above in the absence of detergents. Bound proteins were eluted by boiling samples in Laemmli loading buffer. Immunoprecipitated proteins or, alternatively, detergent-soluble protein lysates, were separated by SDS-PAGE on a 12% acrylamide gel, and proteins were electroblotted onto nitrocellulose membranes. The membranes were washed in Trisbuffered saline with 0.1% Tween, blocked in 5% milk, and incubated with eNOS MAb and caveolin PAb. Membranes were stained with Ponceau S to confirm equal protein loading and transfer between lanes.
NOS activity assay. LX2 cells were lysed in a buffer identical to that described above for preparation of Western blot lysates, then prepared for NOS activity by measuring the conversion of L- It is important to note that the concentrations of calmodulin and CaCl2 were lower in the current study than in prior studies (23) so as to facilitate detection of the inhibitory influence of caveolin on activity of S1179DeNOS, which has lower calcium/calmodulin activation requirements than the wild-type enzyme (11) . Samples were run in duplicate in the presence and absence of N -nitro-L-arginine methyl ester (L-NAME; 1 mM) or vehicle. The reaction was terminated by the addition of 1 ml of cold stop buffer (20 mM HEPES, 2 mM EDTA, 2 mM EGTA, pH 5.5), and the reaction mix was applied to a Dowex AG 50WX-8 resin column. Radiolabeled counts per minute of L-citrulline generation were measured and used to determine L-NAME-inhibited NOS activity.
Statistical analysis. All data are given as means Ϯ SE. Data were analyzed using paired and unpaired Student's t-tests as appropriate.
RESULTS
AdCMVS1179DeNOS potentiates NO production from liver cells in vitro.
To ascertain the NO-producing capacity of S1179DeNOS in liver cells, we first examined NO production from cells transduced with AdS1179DeNOS in vitro. As both NPC and hepatocytes are transduced by adenoviral vectors in vivo (20, 33) , we examined NO production from both these cell populations. In these experiments, overexpression of the vectors was evident by tracking of GFP in transduced cells by fluorescence microscopy ( Fig. 1A ; left, mock transduction; right, AdS1179DeNOS). First, NPC were transduced with adenoviral vectors and cells were stimulated with the Ca 2ϩ ionophore A23187 (10 M). As S1179DeNOS evidences a greater calcium sensitivity compared with wild-type eNOS (11), we examined both basal and agonist-stimulated NO generation from NPC. In NPC, AdS1179DeNOS resulted in greater levels of ionophore-stimulated NO production compared with the GFP control vector, as assessed by NO-specific chemiluminescence (Fig. 1B) . Additionally, basal NO production from cells transduced with AdS1179DeNOS was also increased compared with cells transduced with AdGFP as assessed by Greiss analysis from the media of transfected cells (Fig. 1C) . As hepatocytes are also transduced with adenoviral vectors in vivo (20, 33) , additional studies were performed in these cells as well. Hepatocytes transduced with AdS1179DeNOS produced greater levels of A23187-stimulated NO than hepatocytes transduced with empty GFP vector, as assessed by cheimiluminescence from the culture media (Fig. 1D) . Additionally, excess NO-generating capacity of the constitutively active form of eNOS was evident by the excess NO generation in cells transduced with AdS1179DeNOS compared with cells transduced with AdS1179AeNOS, a control vector that encodes a construct that mimics an unphosphorylatable form of eNOS (18) . In both NPC and hepatocytes, NO generation in cells transduced with AdGFP was comparable with nontransduced native cells (data not shown). These studies indicate that recombinant S1179DeNOS delivered in the form of an adenovirus potentiates NO production from both hepatocytes and NPC and that this construct augments both basal and agonist-stimulated NO production.
S1179DeNOS improves vasodilatory responses in sham rats, but not BDL rats after in vivo transduction
As AdS1179DeNOS transduction of liver cells potentiated NO production, we next sought to examine the influence of S1179DeNOS gene delivery on hepatic vascular responses in the intact rat liver after in vivo transduction. Sham or BDL rats were transduced with AdS1179DeNOS or AdGFP (10 10 pfu into tail vein) ϳ4 wk after surgery. One week later, animals were killed and vascular responses were examined in the isolated perfused liver in response to increasing concentrations of the vasoconstrictor MTX (10 Ϫ6 to 10 Ϫ4 M), an agent that increases both presinusoidal and sinusoidal/postsinusoidal pressure in the perfused rat liver preparation (10). In sham animals, S1179DeNOS overexpression was associated with significantly diminished constriction in response to incremental doses of MTX ( Fig.  2A) , similar to prior studies performed with wild-type eNOS overexpression (20) . However, surprisingly, BDL rats transduced with AdS1179DeNOS did not demonstrate improved vasodilatory responses as evidenced by similar flow-dependent pressure increases as that observed in BDL rats transduced with AdGFP (Fig. 2B) . Similarly, a diminution in constriction in response to incremental doses of MTX was also not detected in BDL rats transduced with AdS1179DeNOS compared with BDL rats transduced with AdGFP (data not shown). Owing to the extensive portasystemic shunting observed after BDL as well as the previously documented difficulties in transfecting liver cells in the injured/cirrhotic liver (32), we next sought to assess the adequacy of transgene expression in livers after in vivo delivery of adenoviral vectors to exclude the possibility that the lack of vasodilatory effect of AdS1179DeNOS in BDL rats may be due to inadequate transgene expression. However, as seen in Fig. 2C , GFP transgene levels were similar in all experimental groups including BDL animals transduced with AdS1179DeNOS and AdGFP as well as sham animals transduced with both these vectors, as assessed by fluorimetric quantification from respective liver lysates. Thus S1179DeNOS Fig. 1 . AdS1179DeNOS promotes nitric oxide (NO) production from nonparenchymal cells (NPC) and hepatocyes in vitro. Freshly isolated NPC or, alternatively, hepatocytes were plated and cultured for 4 h, then transfected with adenoviral vectors. Vectors included adenoviral vector encoding green fluorescent protein (AdGFP) and S1179DeNOS (AdS1179DeNOS) and, in some experiments, S1179AeNOS (AdS1179AeNOS; 50 MOI each vector). After 24 h, media were collected from NPC for analysis of basal NO production by Greiss reaction. Subsequently, cells were stimulated with A23187 (10 M), and agonist-stimulated NO production was assessed by NO-specific chemiluminescence. A: fluorescence microscopy demonstrates the prominent green fluorescent protein (GFP) expression in NPC transduced with AdS1179DeNOS (right) compared with mock transduced cells (left). B: NPC transduced with AdS1179DeNOS produced greater levels of A23187-stimulated NO compared with NPC transduced with AdGFP alone (n ϭ 3 independent cell isolations each performed with duplicate wells and duplicate readings; *P Ͻ 0.05; GFP vs. S1179DeNOS). C: cells transduced with AdS1179DeNOS produced greater levels of basal NO production compared with cells transduced with AdGFP alone (n ϭ 3 independent cell isolations each performed with duplicate wells and duplicate readings; *P Ͻ 0.05; GFP vs. S1179DeNOS). D: akin to NPC, hepatocytes transduced with AdS1179DeNOS produced much greater levels of A23187-stimulated NO compared with cells transfected with AdGFP or AdS1179AeNOS (n ϭ 4 independent cell isolations each performed with duplicate wells and duplicate readings). NOS, NO synthase.
gene delivery augments vasodilatory tendencies in sham animals but does not augment vasodilatory responses in BDL animals, despite adequate transgene expression.
Caveolin-1 is expressed in stellate cells in BDL liver and binds S1179DeNOS. We and others have previously demonstrated that increased expression and eNOS binding of caveolin-1 in liver endothelial cells may contribute to deficient eNOS function in the BDL rat (22) and in human cirrhosis (3, 31) . Because hepatic stellate cells constitute an important target for the vasoregulatory effects of NOS-encoding adenoviral vectors (33), we wondered whether inhibitory signaling events in stellate cells may contribute to deficient function of heterologously expressed recombinant S1179DeNOS. We have previously demonstrated that caveolin is detected in stellate cells in normal liver (22) . To detect for caveolin expression in stellate cells in intact tissue, BDL or sham liver sections were prepared for morphological and immunogold examination using transmission electron microscopy. The lowmagnification electron micrograph of the sinusoids in Fig. 3, A and B , depicts the cells of interest, the sinusoidal endothelial cell in Fig. 3A and the hepatic stellate cell in Fig. 3B . As seen in the higher magnification image in Fig. 3C , analysis of caveolin immunogold particles in sham liver sinusoids did not reveal very prominent detection of gold particles, consistent with our prior light microscopic immunohistochemical analyses for caveolin (22, 23) . As seen in a high-magnification electron micrograph in Fig. 3D , caveolin immunogold particles were more prominent in endothelial cells lining larger vascular structures such as venules as depicted by the gold labeling of nonclathrin-coated endothelial cell vesicles. Caveolin immunogold detection was also more prominent in BDL liver that was analyzed, as evidenced in the higher magnification images in Fig. 3 , E and F, which depict caveolin immunogold particles prominently visible on sinusoidal endothelial cells and hepatic stellate cells, respectively.
Next, to determine whether caveolin expression from hepatic stellate cells, which do not normally express eNOS (16, 21) , could influence the function of recombinantly expressed S1179DeNOS, we performed in vitro studies in the LX2 hepatic stellate cell line. Cells were cotransfected with AdS1179DeNOS, AdCav, empty vector, or combinations of these vectors and prepared for immunoprecipitation analysis using eNOS MAb or, alternatively, caveolin PAb. As seen in Fig. 4A , top, immunoprecipitation of caveolin coprecipitates S1179DeNOS (lane 3) from cells cotransduced with AdCav and S1179DeNOS but does not coprecipitate eNOS in cells transduced with only AdCav (lane 2) or only empty vectors (lane 1). Figure 4A , bottom, displays the corresponding Western blot analysis from total cell lysates from each of the experimental groups demonstrating overexpression of myc-tagged caveolin (larger molecular weight band in lanes 2 and 3) and overexpression of S1179DeNOS (lane 3). Furthermore, as seen in Fig. 4B , immunoprecipitation of eNOS in cells transduced with AdS1179DeNOS coprecipitates small amounts of caveolin (lane 2), and caveolin coprecipitation is further enhanced upon cotransduction of these cells with AdCav (lane 3). Figure 4B , bottom, displays the corresponding Western blot analysis from total cell lysates from each of the experimental groups demonstrating overexpression of myc-tagged caveolin (larger molecular weight band in lane 3) and overexpression of S1179DeNOS (lanes 2 and 3) . To examine whether caveolin-1 overexpression and enhanced binding with S1179DeNOS influences NOS function, NOS activity was assayed in LX2 cells transfected with ] from liver lysates. GFP levels were increased to similar levels in both sham and BDL animals injected with either AdGFP or AdS1179DeNOS (which encodes GFP as well as S1179DeNOS; n ϭ 3-5 samples from each experimental group, each examined in duplicate). S1179DeNOS alone or with S1179DeNOS in conjunction with caveolin-1. As seen in Fig. 4C , caveolin overexpression resulted in a significant reduction in the catalytic activity of S1179DeNOS. These studies indicate that heterologously expressed recombinant S1179DeNOS interacts with the eNOS inhibitory protein caveolin, endogenously expressed in LX2 cells, and furthermore that increases in caveolin levels, as observed after BDL (22) and as mimicked in these studies by recombinant caveolin-1 overexpression, promote further binding of caveolin with S1179DeNOS in these cells and diminish NOS activity.
DISCUSSION
Regulation of eNOS requires multiple molecular steps that include putative protein interactions with heat shock protein 90, caveolin, dynamin, and others, as well as serine phosphorylation and appropriate subcellular targeting (7) . In this regard, adenoviral-based overexpression of NOS isoforms in vivo and in vitro have allowed for better understanding of eNOS signaling pathways, the mechanisms of NOS function in liver, as well as eNOS dysfunction in cirrhosis (20, 29, 33) . In this study, we exploited the recent availability of a constitutively active form of eNOS, S1179D, encoded in an adenoviral vector (11) , to better ascertain the function of eNOS in the cirrhotic liver. Constitutive activation occurs by virtue of mutation of serine 1179 on eNOS to aspartate, with the negative charge conferred by aspartate mimicking AA 1179 phosphorylation, a key step in eNOS activation (5, 6) . Prior studies have demonstrated that S1179DeNOS produces higher levels of NO compared with the wild-type eNOS, owing to enhanced calcium sensitivity and reductase domain electron transfer of the enzyme (11, 18 ). Our studies demonstrate that S1179DeNOS delivered via an adenoviral vector promotes NO generation in both parenchymal cells and NPC and augments hepatic vasodilatory responses when delivered in vivo in normal rats and are consistent with the aforementioned studies, as well as our own prior studies (20) that demonstrated a vasodilatory capacity of a wild-type eNOS construct delivered to rats in vivo.
Interestingly, a vasodilatory influence of S1179DeNOS in cirrhotic liver was not evident from the current study. The lack of functional effect of S1179DeNOS in cirrhotic liver suggests that the posttranslational processing defects of endogenous hepatic eNOS protein evident in prior studies (16, 22) also abrogates activity of exogenously delivered S1179DeNOS protein. This hypothesis is supported by the demonstration that in hepatic stellate cells, which are a key target cell for systemically delivered adenoviral vectors (32, 33) , the NOS inhibitory protein caveolin binds to exogenously delivered S1179DeNOS and that increases in cellular caveolin levels in these cells via adenoviral-based overexpression result in even greater binding interactions. These studies highlight the dependence of eNOS function on appropriate posttranslational processing rather than on absolute levels of the protein (7) and are consistent with prior studies that have failed to demonstrate a deficiency of eNOS protein levels in this model of portal hypertension despite deficient NO generation (16, 23) . It has been recently demonstrated that overexpression of an adenoviral vector encoding wild-type eNOS protein improves portal hypertension in a chemical model of experimental cirrhosis (29) , and, consistent with the aforementioned considerations, the model used in that study was, by those authors, characterized by a deficiency of eNOS protein levels within the cirrhotic liver. The deficiency in eNOS protein levels may thereby account for the beneficial influence of eNOS gene delivery in that study (29) , although alternative explanations such as differences in viral vector or method of delivery may also account for the differences in results between that study and our study. Interestingly, prior studies (33) have demonstrated that delivery of the neuronal NOS gene to cirrhotic liver via adenoviral vector also partially corrects deficient NO production and NO-deficient hepatic vasodilatory responses that characterize the cirrhotic liver. The contrasting effects of eNOS and nNOS gene delivery in cirrhosis highlight the prominent distinctions of the activation processes of these two NOS isoforms. In this context, future studies examining the influence of gene delivery of the high NO-generating inducible NOS isoform on hepatic vascular responses in cirrhotic liver will be of interest.
It is possible that resistance to efficient cell transduction of AdS1179DeNOS in the BDL liver (32) or inadequate viral titering due to portasystemic shunting may partially account for the difficulty in promoting vasodilatory responses in the BDL liver. However, the detection of similar levels of transgene overexpression in BDL liver compared with sham liver reduces this likelihood in our study. Analysis of effect with higher viral titers would be desirable; however, this option is limited by excess inflammatory responses induced by excess adenoviral vector titering. Thus fu- . Cav doublet bands, when present, reflect endogenous Cav (lower molecular weight) and exogenous Cav, which is detected as a slightly higher molecular weight protein owing to the myc-tagged construct. C: eNOS activity in LX2 cells transduced with AdS1179DeNOS and AdCav was diminished compared with LX2 cells transduced with AdS1179DeNOS ϩ equivalent MOI of empty vector control (*P Ͻ 0.05; S1179DeNOS vs. S1179DeNOS plus Cav; n ϭ 5 experiments each performed in duplicate).
ture studies using alternative vector systems with higher and longer duration of overexpression might result in a greater vasodilatory response in cirrhotic liver transduced with eNOS gene than that which we observed using traditional adenoviral vectors and are worthy of pursuit.
In rodents, systemic delivery of adenovirus results in prominent hepatic delivery with transduction of multiple liver cell types to varying degrees, including hepatic stellate cells (20, 33) . Transduction of these cells is particularly intriguing, because these cells contain the downstream signaling targets, including soluble guanylate cyclase, necessary to influence vascular tone in response to NO as well as other vasodilator molecules such as CO (14, 15, 19, 26, 28) . We and others (3, 22, 23, 31) have previously demonstrated that caveolin-1 protein abundance is increased in cholestatic and noncholestatic models of chronic liver injury and cirrhosis within liver endothelial cells and that this may contribute to deficient hepatic eNOS activity in these models. The mechanism of caveolin upregulation remains uncertain but does not appear to be secondary to bile acids, at least as evidenced by a lack of bile acidmediated stimulation of caveolin promoter activity as assessed by a reporter assay in transfected cells (S. Cao and V. Shah, unpublished data). The current studies demonstrate, by immunoelectron microscopy, that caveolin expression also occurs in stellate cells in the BDL liver. This is not entirely surprising, because caveolin has been previously demonstrated in pericytes and smooth muscle cells in other organs (2) . As stellate cells are readily transduced with intravenously administered adenoviral vectors and may be the target cell by which NOS gene delivery imparts beneficial vasodilatory actions (32, 33) , we anticipate that increases in caveolin, not only in liver endothelial cells but also in other perisinusoidal cells including hepatic stellate cells, may contribute to the inability of S1179DeNOS to promote vasodilatory responses in the transduced BDL liver. This hypothesis is supported by our in vitro studies in LX2 hepatic stellate cells in which, overexpression of caveolin-1 is associated with increased association of caveolin with recombinant S1179DeNOS and diminished NOS activity. These studies suggest that potentiation of eNOS -derived NO generation in the cirrhotic liver may be more likely achieved by modulating the signaling of existing eNOS protein through approaches that dissociate the inhibitory eNOS-caveolin interaction or that potentiate the phosphorylation of existing eNOS protein, rather than by delivering excesses of eNOS protein, and recent studies (12a) using gene delivery of activated Akt in liver cirrhosis support this concept. Alternatively, molecular or pharmacological targets downstream of NOS generation, such as activation of guanlyate cyclase, remain an area of further investigation.
In summary, the present study provides important insights into the function of hepatic eNOS in the cirrhotic liver by demonstrating that 1) overexpression of a constitutively active form of eNOS potentiates NO production from both hepatocytes and NPC and promotes hepatic vasodilatory responses when injected in vivo, and 2) constitutively active recombinant eNOS does not function optimally in the context of the cirrhotic liver, perhaps, in part, because of the inhibitory influence of excess caveolin protein levels within adenovirally transduced cells, including hepatic stellate cells.
